The company has been studying the peptides, in combination with the company’s patented Oxiplex gel as a delivery vehicle, for use in bone growth applications. The promising results of the studies have been reported at leading surgical congresses.
FzioMed said that it will pursue development of the peptides across all potential applications and that future products will be designed for use in orthopedic, spine, trauma, joint reconstruction and sports medicine.
The worldwide license covers proprietary, synthetic oligopeptides that have been studied in a variety of preclinical settings for osteo-induction in bone healing.
“FzioMed sees significant market opportunities for injectable bone growth factors with osteo-inductive properties,” said Dr Richard Berg, vice president of R&D for FzioMed. “These new peptides, combined with our synthetic gels for injectable delivery, will be the basis for FzioMed products that meet an important medical need.”